CAJ | 학술논문

胰高血糖素样肽-1（GLP-1）受体激动剂（GLP-1RA）艾塞那肽（exenatide）和利拉鲁肽（liraglutide）的作用机制是增加胰岛素分泌，抑制胰高血糖素释放，减轻胰岛素抵抗，抑制食欲并减缓胃排空。这些降糖作用具有葡萄糖浓度依赖性可避免严重低血糖。除了有确切的降糖作用外，还有降血压、保护心血管、减轻脂肪肝、调脂和减轻体质量的作用，动物实验中，这类药物有助于保护β细胞功能，可以安全地与二甲双胍、磺酰脲类药物、噻唑烷二酮类和胰岛素联合治疗糖尿病，其代表性药物利拉鲁肽和艾塞那肽为控制高血糖和降低体质量提供了另一种治疗选择。
이고혈당소양태-1（GLP-1）수체격동제（GLP-1RA）애새나태（exenatide）화리랍로태（liraglutide）적작용궤제시증가이도소분비，억제이고혈당소석방，감경이도소저항，억제식욕병감완위배공。저사강당작용구유포도당농도의뢰성가피면엄중저혈당。제료유학절적강당작용외，환유강혈압、보호심혈관、감경지방간、조지화감경체질량적작용，동물실험중，저류약물유조우보호β세포공능，가이안전지여이갑쌍고、광선뇨류약물、새서완이동류화이도소연합치료당뇨병，기대표성약물리랍로태화애새나태위공제고혈당화강저체질량제공료령일충치료선택。
Glucagon like peptide-1 (GLP-1) receptor agonists (GLP-1RA), exenatide and liraglutide, exert their hypoglycemic effects by enhancing the secretion of insulin, inhibiting the release of glucagon, reducing insulin resistance, suppressing appetite and inhibiting gastric emptying. These effects are in a glucose level-dependent manner so as to prevent severe hypoglycemia. In addition to these definite hypoglycemic effects, the agents also decrease blood pressure, protect heart and blood vessels, attenuate fatty liver and reduce body mass. In animal experiments, these GLP-1RA drugs protect the function of β cells, and are safely combined with metformin, sulfonylureas, thiazolidinediones and insulin in the treatment of diabetes. Exenatide and liraglutide, as representatives of GLP-1RA, are a good option to control blood glucose and reduce body mass for diabetic patients.